UNSPSC 51393105: Guanabenz acetate

This classification denotes an antihypertensive agent with the molecular formula C8H8Cl2N4.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 443O19GK1A, chemically known as (2,6-dichlorophenyl)methylideneaminoiminomethanediamine but more generally known as guanabenz acetate, which bears US NIH Compound Identifier 3517. European Medicines Agency schedules Guanabenz acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02423MIG.

Most nations, for tariff and trade purposes, schedule guanabenz acetate under HS 29280090 and SITC 51486. As of Q4 2014, GUANABENZ ACETATE remains US FDA's Preferred Term for this commodity. Guanabenz acetate bears US NLM identifiers UMLS ID C0733381 and NCI Concept Code C65826. SMILES: CC(=O)O.C1CC(C(C(C1)CL)/C=N/NC(=N)N)CL.

UNSPSC 51393105 Guanabenz acetate is a Commodity code that does not align with the state and local procurement activity currently posted under it. The one recent opportunity tagged to this code—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026—solicits naloxone and drug deactivation systems, not guanabenz acetate, a branded antihypertensive pharmaceutical. The mismatch suggests a data entry or classification error in the source system rather than genuine market activity for guanabenz acetate at the state and local level. Guanabenz acetate remains a narrow-use pharmaceutical with limited procurement visibility in public-sector notices; state and local health departments, correctional systems, and purchasing consortia that do source pharmaceuticals typically use GPO agreements, state pharmaceutical contracts, or cooperative purchasing arrangements rather than individual competitive bids.

No state or local procurement opportunities for guanabenz acetate itself appear in recent notice activity. The single record present—Seminole County's naloxone and safe drug deactivation system procurement due July 26, 2023 (note: the due date predates the posting date, indicating a data quality issue in the source)—represents unrelated pharmaceutical and harm-reduction equipment, not the code's stated commodity. Business development professionals monitoring this code should verify internal classification protocols and confirm whether the actual procurement target is guanabenz acetate or a broader pharmaceutical supply or controlled-substance management contract.